Structural investigations on lipid nanoparticles containing high amounts of lecithin

Schubert, M.; Harms, Meike; Müller‐Goymann, Christel C.

doi:10.1016/j.ejps.2005.10.004

Cited by 121 publications

(61 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this case, the nanoparticles were prepared by cold homogenization which may have prevented a redistribution of the lecithin to the surface of the particles or into the aqueous phase. Such a behaviour could be observed for a similar system after high pressure homogenization of the molten lipids [28].…”

Section: Friedrich Et Al [ 2 7 ] R E P O R T E D a D I F F E R E N T supporting

confidence: 58%

“…In solid lipid nanoparticle dispersion, additional liposomes were observed by means of cryo-TEM, although the amount was lower than in a corresponding emulsion [72]. In contrast to this, Schubert et al [73] performed NMR, TEM and small angle X-ray scattering (SAXS) measurements and showed that no additional colloidal structures were formed. Drug nanocrystals could also be formed when the amount of the drug present far exceeds its solubility limit in the lipid matrix.…”

Section: Coexistence Of Other Colloidal Structures In the System (Egmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development

Attama¹,

Momoh²,

Builders³

2012

Recent Advances in Novel Drug Carrier Systems

View full text Add to dashboard Cite

Section: Friedrich Et Al [ 2 7 ] R E P O R T E D a D I F F E R E N T supporting

confidence: 58%

Section: Coexistence Of Other Colloidal Structures In the System (Egmentioning

confidence: 99%

Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development

Attama¹,

Momoh²,

Builders³

2012

Recent Advances in Novel Drug Carrier Systems

View full text Add to dashboard Cite

“…Their use in the development of LN dispersions is essential to decrease the interfacial tension between the oil phase and the internal and external aqueous phase, and also to facilitate the emulsification of the lipid matrix. Lecithin is used due to its higher power of emulsification able to provide a very good stabilization of the oil-in-water interfaces and has also been reported to decrease particle size in emulsions that is mainly explained by its amphiphilic character (Trotta et al, 2002;Schubert et al, 2006;Kawaguchi et al, 2008). The lipophilic portion of lecithin dissolves the lipid phase, i.e.…”

Section: Resultsmentioning

confidence: 99%

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Fangueiro

Andreani

Egea

et al. 2014

International Journal of Pharmaceutics

131

View full text Add to dashboard Cite

a b s t r a c tIn the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5 wt% of CTAB.

show abstract

“…SLN were proposed for brain drug-targeting application independently by two research groups (i.e. Schöler et al, 2001;Schubert et al, 2006). Delivering drugs to the CNS is impaired by the presence of the BBB that represents the main obstacle for CNS drug development.…”

Section: Introductionmentioning

confidence: 99%

Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease

Bhatt¹,

Singh²,

Prakash

et al. 2014

Drug Delivery

117

View full text Add to dashboard Cite

Objective: The objective of the present study was to investigate the potential use of solid lipid nanoparticles (SLNs) as a drug delivery system to enhance the brain-targeting efficiency of rosmarinic acid (RA) following intranasal (i.n.) administration. Materials and methods: The RA-loaded SLNs was prepared by the hot homogenization technique, in which glycerol monostearate (GMS) as lipid, tween 80 and soya lecithin were used as surfactant along with hydrogenated soya phosphatidyl choline (HSPC) as a stabilizer, and were characterized for particle size, zeta potential (ZP), in vitro study. Nasal delivery of the developed formulation followed by the study of behavioral (locomotor, narrow beam, body weight) and biochemical parameters (glutathione, lipid peroxidation, catalase and nitrite) in wistar rat was carried out. Results: Optimized RA-loaded SLNs using tween 80 (SLNPRT) have the mean size of (149.2 ± 3.2 nm), ZP (À38.27 mV) entrapment efficiency (61.9 ± 2.2%). 3-NP-treated rat significantly increased behavioral alterations, oxidative damage as compared with the control group. SLNPRT treatment significantly improved behavioral abnormalities and attenuated the oxidative stress in 3NP-treated rats. However, the nasal delivery of SLNPRT produced significant therapeutic action as compared to intravenous application. In the organ distribution study, brain drug concentration was found to be 5.69 mg, in pharmacokinetic study C max , t max , t 1/2 , AUC values were found to be 0.284 mg/ml, 1.5 h, 3.17 h, and 1.505 mg/ml/h, respectively. Conclusion: The encouraging results confirmed the developed optimized RA-loaded SLNs formulation following the non-invasive nose-to-brain drug delivery that is a promising therapeutic approach for the effective management in Huntington disease.

show abstract

Structural investigations on lipid nanoparticles containing high amounts of lecithin

Cited by 121 publications

References 23 publications

Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development

Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease

Contact Info

Product

Resources

About